Background: In a randomized study, we observed a higher incidence of biopsy-proven acute rejection with preemptive valganciclovir therapy as compared with valacyclovir prophylaxis for prevention of cytomegalovirus (CMV) disease after renal transplantation (RTx). Persistence of the virus within the allograft could stimulate the alloimmune response. The aim of our study was to evaluate intragraft CMV infection in patients randomized to the trial. Methods: RTx recipients at risk of CMV were randomized to pre-emptive therapy with valganciclovir (n=36) for significant CMV viraemia (≥2,000 copies/ml by quantitative PCR in whole blood samples) or 3-month prophylaxis with valacyclovir (n=34). Renal biopsies performed during 12 months post-RTx were analysed for the presence of CMV by real-time PCR and immunohistochemical staining.
Cytomegalovirus (CMV) disease is a common infectious complication in patients after solid organ transplantation. The past decade witnessed major advances in CMV disease prevention [1] . Use of universal prophylaxis or preemptive therapy has resulted in a decrease in the incidence of CMV disease from 20-60% to 5-20% [2, 3] ; however, the efficacy of preventive approaches in terms of indirect effects of CMV occurrence remains problematic. Association with allograft rejection belongs to well-documented and clinically important indirect effects of CMV, with a prolonged adverse effect on graft survival [4] . Prospective studies in patients undergoing renal transplantation (RTx) have shown that both CMV disease and asymptomatic CMV viraemia are independent risk factors for the onset of acute rejection [5, 6] . Asymptomatic viraemia increases the presence of interstitial fibrosis and tubular atrophy in protocol biopsy as early as 3 months post-RTx [7] . CMV infection has even prevented anti-CD4 monoclonal antibody-induced tolerance in a rat RTx model [8] . By contrast, an adequate level of CMV-specific T-cell immunity, primarily in the early post-RTx period, has a protective effect not only for the subsequent development of CMV disease or viraemia with a high viral load, but also on the onset of acute and chronic rejection [9] [10] [11] [12] [13] .
Randomized studies have demonstrated the efficacy of both universal prophylaxis and pre-emptive therapy in the prevention of CMV disease [14] [15] [16] [17] [18] [19] [20] . The introduction of valganciclovir instead of intravenous ganciclovir 
Introduction
into clinical practice has made provision of pre-emptive therapy simpler [21] ; however, pre-emptive therapy is associated with a higher incidence of asymptomatic CMV viraemia [18] [19] [20] . Data from recent randomized trials have shown increased risk of acute rejection and poorer long-term graft survival with pre-emptive therapy compared with prophylaxis [19, 20] . Although the results of these trials have been fairly inconsistent, some authors have been able to document persistent CMV infection in biopsy specimens of renal allografts in a significant proportion of patients as late as several months after CMV was last detected in blood [22, 23] . CMV infection in renal allografts has been associated with deteriorated graft function and poorer survival [23] .
Our study was designed to compare valacyclovir prophylaxis with pre-emptive valganciclovir therapy. We observed an increased incidence of CMV viraemia as well as more than a twofold increase in the number of episodes of biopsy-proven acute rejection (BPAR) with pre-emptive therapy [19] . The aim of the present study was to compare the incidence of CMV infection within allografts in patients treated with valacyclovir prophylaxis with those managed by pre-emptive therapy. For this purpose, all renal biopsy specimens obtained from patients included in the study within the first year postRTx were tested for the presence of CMV.
Methods

Study design
A post hoc analysis was performed on the results of a randomized study comparing pre-emptive valganciclovir therapy and valacyclovir prophylaxis in the prevention of CMV disease after RTx [19] . The study was approved by the local ethics committee and conducted in compliance with the Declaration of Helsinki. Written informed consent was obtained from all patients. The method has been described in detail earlier [19] . Briefly, patients were randomized to pre-emptive therapy with valganciclovir or to valacyclovir prophylaxis. Valacyclovir (Valtrex; Glaxo Wellcome, Dartford, UK) was given at a dose of 2 g 4× daily for 3 months. All patients were monitored using quantitative real-time PCR from whole blood for CMV viraemia using a commercially available kit (RealArt™ CMV RG PCR Kit; Artus, Hamburg, Germany). In the pre-emptive group, valganciclovir (Valcyte; Hoffman-La Roche, Grenzach-Wyhlen, Germany) was administered at a dose of 900 mg twice daily if a viral load of ≥2,000 copies/ml was detected.
Detection of cytomegalovirus in allograft biopsy specimens
Both indication and protocol biopsies performed as part of the study were tested for the presence of CMV. Indications for biopsy included an increase in serum creatinine by >20%, delayed graft function and also suboptimal development of graft function (serum creatinine level >160 µmol/l). Protocol biopsy was performed 3 months after RTx. Tissues for light microscopy were fixed in 4% formaldehyde and embedded in paraffin using routine procedure. Sections (5 µm thick) were cut from tissue blocks and stained with haematoxylin and eosin, blue trichrome, silver staining and Congo red staining. All biopsies were evaluated according to the Banff 05 classification [24] .
For the detection of CMV DNA in allograft biopsy specimens, DNA from formalin-fixed, paraffinembedded tissues was extracted using a NucleoSpin Tissue kit (Macherey Nagel, Duren, Germany) according to the manufacturer's protocol. In several cases where the amount of extracted DNA was low, microconcentration with Microcon 100 (Millipore, Billerica, MA, USA) according to the manufacturer's protocol was carried out. The integrity of DNA was verified by multiplex amplification for detection of control genes producing fragments from 100 to 600 base pairs (bp) [25] . The presence of CMV DNA was analysed by real-time PCR using an Artus CMV RG PCR kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. PCR products with a length of 105 bp were detected by FAM-labelled probes in appropriate channels on a Rotor-Gene™ 2000/3000 device (Corbett Research, Sydney, Australia). As an internal quality control, a heterologous amplification system analysed in channel JOE was used. The samples were considered positive when both controls and analysed curves exceeded a defined threshold (≥0.1 copies/µl of reaction). Moreover, immunohistochemical staining was performed using primary antibody against CMV antigen (monoclonal CCH2, 1:100; DakoCytomation, Glostrup, Denmark). The primary antibody was visualized using the supersensitive streptavidin-biotin-peroxidase complex (Biogenex, San Ramon, CA, USA). Appropriate positive control of the tissues used with the corresponding primary antibody were employed. Physicians assessing the results of tissue CMV analysis were blinded both to the study group of patients and CMV viraemia status.
Study end points
The primary end point was the 12-month incidence of CMV infection in the renal allograft. Intragraft CMV infection was defined by positive tissue PCR and/or positive immunohistochemistry. Secondary end points included relationships between CMV viraemia and CMV detection in the biopsy specimens. Additionally, dependence of the histological finding of acute rejection on the presence of CMV within the allograft was analysed.
Statistical analyses
The incidence of intragraft CMV infection was calculated using Kaplan-Meier curves with the log-rank test used for comparison. Quantitative parametric data were compared between the groups using Student's t-test and the Mann-Whitney U test in non-parametric distribution. Qualitative data were analysed using Fisher's exact or χ 2 tests. Data were analysed according to the intention-to-treat principle. Statistical calculations were made using SPSS (Systat Software, Chicago, IL, USA) for Windows version 3.10 software. Values of P<0.05 were considered as statistically significant.
Results
Patient and biopsy characteristics
All 70 patients included in the original study were considered for analysis for the presence of CMV in renal allograft biopsies [19] . A flow chart of the patients is shown in Figure 1 . A total of 72 biopsy specimens were obtained from 36 patients randomized to pre-emptive therapy. Of these 72 biopsies, at least one biopsy specimen with successful DNA extraction was available from 35 patients (the total number of biopsies was 59). The number of biopsies performed in the valacyclovir prophylaxis was 73 (n=34). Sufficient amounts of material for DNA extraction for PCR CMV analysis was available from 31 patients (number of biopsies was 57).
Of the total of 116 analysed biopsy specimens, 61 (53%) were clinically indicated and 55 (47%) were by protocol. The mean time of obtaining biopsy specimens in patients receiving pre-emptive valganciclovir therapy and those treated with valacyclovir prophylaxis was similar (mean ±sd 66 ±45 versus 79 ±76 days post-RTx; P=0.931). Results of histology are shown in detail in Table 1 . 
Incidence of intragraft cytomegalovirus infection
Within the first year post-RTx, CMV was detected in the biopsy specimens of five patients of the pre-emptive valganciclovir therapy group and two patients receiving valacyclovir prophylaxis. All seven patients were positive by tissue PCR, whereas immunohistochemistry was positive in one patient only. This patient also showed CMV inclusions in histology and increases of serum creatinine compatible with diagnosis of CMV nephritis. Cumulative incidence, as assessed using the Kaplan-Meier method, was 14% and 7% with pre-emptive therapy and prophylaxis, respectively ( Figure 2) . The difference was not statistically significant (P=0.315). Among the 59 biopsy specimens analysed in the pre-emptive group, presence of CMV was demonstrated in 5 (8%) patients, with the figure being 2/57 (4%) in biopsy patients with valacyclovir prophylaxis (P=0.454). No significant differences were likewise noted when assessing only biopsy specimens obtained because of impaired graft function (3/30 versus 1/31; P=0.346).
CMV viraemia was present in all patients but one with CMV evidence within the allograft ( Table 2 ). In that patient, biopsy was performed 4 months post-RTx. Previously (day 36 post-RTx), he had been treated with ganciclovir for CMV syndrome with virus clearance. CMV PCR in whole blood was tested 11 days before and 3 days after biopsy with negative results. Nonetheless, at 52 days post-biopsy, there was recurrence of CMV viraemia that eventually resulted in CMV colitis.
Intragraft CMV infection occurred in 4/10 (40%) patients at risk of primary CMV infection with a CMV serological donor-positive and recipient-negative 
Effects of CMV viraemia on intragraft CMV infection
Within 1 year post-RTx, CMV viraemia developed in 32 (91%) patients with pre-emptive therapy and in 18 (60%) patients receiving prophylaxis (P<0.001). Time to onset of viraemia was delayed by prophylaxis (mean ±sd 37 ±22 versus 181 ±110 days; P<0.001). CMV viraemia preceded biopsy in 37 (63%) patients of preemptive therapy and 6 (11%; P<0.001) patients receiving prophylaxis. At the time of biopsy, CMV viraemia was detected in 18 (31%) biopsy specimens from the preemptive valganciclovir therapy group compared with only 3 (5%) biopsy specimens (P=0.001) obtained from patients with valacyclovir prophylaxis.
With biopsies preceding CMV viraemia (n=43), CMV in allograft was detected in 7 (16%) patients. Intragraft CMV infection never developed unless preceded by viraemia (P=0.002; Table 3 ). In patients with CMV viraemia present at the time of biopsy (n=21), CMV was detected in the allografts of 6 (29%) biopsy specimens. In patients with negative CMV viraemia at the time of biopsy (n=95), CMV in allograft was detected in only 1 (1%) patient (P<0.001). Importantly, if CMV viraemia was present prior to biopsy but virus clearance was confirmed by the time of biopsy, intragraft CMV infection was uncommon (1/37 [3%]).
Intragraft CMV infection, allograft rejection and allograft outcome
No significantly higher incidence of BPAR was noted in biopsy specimens with evidence of CMV infection; however, the number of biopsies was low precluding relevant statistical analysis (2/7 [29%] versus 17/109 [16%]; P=0.710). In addition, CMV viraemia at the time of biopsy (P=0.179) or prior to biopsy (P=0.812) was not associated with an increased risk of BPAR. Similar findings were made in cases of histologically documented borderline changes (Additional file 1). Cumulative 12 months incidence of BPAR was numerically higher in patients suffering from intragraft CMV infection (43% versus 24%; P=0.362). Moreover, impaired graft survival at 3 years post-RTx was observed in patients with intragraft CMV infection compared with those without CMV within allograft (57% versus 88%; P=0.014). Nevertheless, these results are based on seven patients only.
Discussion
Results of our study failed to support the hypothesis whereby a high incidence of asymptomatic CMV viraemia in patients managed by pre-emptive therapy might result in intragraft CMV persistence. If this were the case, local production of proinflammatory cytokines induced by intragraft CMV infection [26] could explain the increased risk of acute allograft rejection we observed with pre-emptive therapy [19] . Despite the use of highly sensitive real-time PCR, intragraft CMV infection was demonstrated in only 10% of patients (6% of biopsies), as opposed to the >70% incidence of CMV viraemia. CMV detection rates in biopsy specimens were not significantly increased with pre-emptive valganciclovir therapy compared with valacyclovir prophylaxis. Importantly, intragraft CMV infection was associated, in all cases but one, with the presence of CMV viraemia. In the event of spontaneous or pre-emptive valganciclovir therapyinduced virus clearance, CMV was detected in only 1 of the 37 subsequent biopsies, a finding inconsistent with prolonged CMV persistence in allograft in our patients. Although statistically significant and consistent with report of Helanterä et al. [23] , lower 3-year graft survival in patients with intragraft CMV infection observed in our study should be interpreted with caution. The result is based on seven patients only, precluding multivariate analysis and only such an analysis might prove intragraft CMV infection as an independent risk factor for long-term graft failure. Although in animal experiments intragraft CMV infection has been repeatedly demonstrated together with signs of enhanced local inflammatory response, consistent data from human studies are not available [26] [27] [28] . In contrast to our study, Helanterä et al. [22] reported intragraft CMV in 44% of patients with previous CMV infection [22] . Having analysed data from an enlarged series, the authors subsequently reported a reduced graft survival in patients with persisting intragraft CMV infection detected in biopsy specimens obtained >2 months after the last detection of CMV viraemia [23] ; however, their group of patients was substantially different from ours. In the absence of CMV prophylaxis or pre-emptive therapy, while indicating CMV pp65 antigenaemia or viral cultures only in the event of suspected clinical signs of CMV infection, symptomatic CMV disease was present in almost 90% of enrolled patients, with repeated episodes in a substantial proportion of individuals [22] . A high incidence of intragraft CMV infection is to be expected in a population at such excess risk. By contrast, our patients received prophylaxis or pre-emptive therapy, which effectively prevents the development of CMV disease while allowing only low-grade CMV viraemia [18, 19] .
CMV has long been known to stimulate alloimmune response and raises the risk of developing both acute and chronic allograft rejection [1, [5] [6] [7] 26] . Despite this, the immunological mechanisms of CMV-induced allograft rejection remain to be a matter of controversy. The hypothesis of heterologous immunity is based on the fact that previous immunological exposure and resultant T-cell memory might affect future immune response to unrelated pathogens [29] , assuming cross-reactivity of CMV-specific T-cells with donor major histocompatibility complex (MHC)-peptide complexes [30] . This theory could explain the prevention of allograft tolerance from developing in an animal model as a result of CMV infection [8] . Nonetheless, in the clinical setting, early development of CMV-specific T-cell immunity confers protection against the development of significant CMV viraemia [9, 11, 13] . The most important finding is that detection of CMV-specific T-cells as early as the first month post-RTx was associated with a lower risk of acute rejection and allograft vascular disease [13] . Moreover, a recent study has shown that patients with high levels of CMV-specific T-cells have a lower donor-reactive T-cell response and improved graft function [12] . These data suggest the key role of suppressed CMV replication and the beneficial effect of adequate CMV-specific immune response on allograft outcome. Moreover, CMV is involved in alloimmunity stimulation through activation of local inflammatory response. The main mechanism is transactivation of nuclear factor-κB (NF-κB) [26] . NF-κB plays a pivotal role in the regulation of a number of cytokine genes and adhesion molecules. CMV induces, through NF-κB activation, expression of adhesion molecules, MHC class I and proinflammatory cytokines [26, 27, 31] . The failure of a number of authors as well as the present study to detect CMV in allograft in a significant number of recipients does not necessarily rule out an ability of CMV to modulate local inflammatory pathways [28] . CMV effects on adaptive and innate immune response not requiring active presence of the virus within the allograft are just another concept under study. NF-κB activation might occur by mere interaction of viral envelope glycoproteins with cell membrane receptors [32] . As part of this concept, suppression of CMV viraemia plays a central role in preventing stimulation of alloimmunity. The lack of intragraft cytokine expression measurement is a limitation of our study; such data might clarify the hypothesis mentioned above.
A strength of our study is that differences in the incidence of intragraft CMV infection between preemptive therapy and prophylaxis were assessed in a randomized population. Moreover, given the high number of indication biopsies and use of protocol biopsy, a biopsy specimen for CMV detection was available in the vast majority of patients. Ours is the first study to compare, using a randomized design, intragraft CMV infection in pre-emptive therapy and prophylaxis. By contrast, a post hoc analysis has its inherent limitations that should be pointed out for interpretation of results to be correct. The study was not powered to detect a statistically significant difference in the incidence of intragraft CMV infection. By retrospective power calculation based on the incidence of intragraft CMV infection in our population, 137 patients per arm would be required to reach statistical significance. In our group, CMV was detected in allograft numerically more often in patients receiving pre-emptive therapy (14% versus 7%). This difference is not likely to explain the higher risk of acute rejection. The incidence of acute rejection was more than twice that of intragraft CMV infection [19] . Like other authors, we did not have more frequent histological findings of acute rejection in CMV-positive biopsy specimens [22] . The finding that the presence of CMV in allograft was associated with CMV viraemia might underestimate the true incidence of intragraft CMV infection in patients with valacyclovir prophylaxis. Although, in the pre-emptive valganciclovir therapy group, biopsy often coincided with CMV viraemia in progress, the delayed development of CMV viraemia in patients with prophylaxis resulted in the overwhelming majority of biopsies performed before the onset of CMV viraemia. Although the overall incidence of CMV viraemia was lower with prophylaxis compared with pre-emptive therapy, it was still detected in >50% of patients, similar to other studies of CMV prophylaxis [14, 15] . In terms of methodology, the exact cumulative incidence of intragraft CMV infection is difficult to establish. In clinical practice, it is impossible to perform graft biopsy during each episode of CMV viraemia and thereby identifying all potential cases of intragraft CMV infection. By contrast, as biopsy specimens contain blood elements, one cannot rule out cases of CMV detection that are inconsistent with true intragraft CMV infection. We and others found a higher detection rate of CMV within allograft using tissue PCR as compared with immunohistochemistry or in situ hybridization [33] . CMV inclusions, positive immunohistochemistry and/or in situ hybridization, however, did not correlate with the level of viral load in blood [33] . Also, our case of intragraft CMV infection with negative CMV viraemia argues against simple interpretation of positive tissue PCR as a detection of CMV in blood components within allograft. Remarkably, end organ CMV disease without CMV in blood has been reported by others [34] .
The appreciably higher incidence of intragraft CMV infection (40% versus 5%) in patients at risk of primary CMV infection could be expected considering the limited ability of the immune system to control virus replication and the known high risk of both early and late onset CMV disease in this population [1] . However, the number of D + /R -patients in our study was small so larger studies are warranted to confirm our results.
In conclusion, the incidence of intragraft CMV infection, and persistent intragraft infection in particular, in RTx patients managed by pre-emptive valganciclovir therapy and/or receiving valacyclovir prophylaxis is low. Compared with prophylaxis, preemptive therapy is not associated with a higher risk of intragraft CMV infection. Our data do not support the theory that the higher risk of acute rejection with pre-emptive therapy is a result of frequent and prolonged intragraft CMV infection. Because our study was underpowered, a large multicentre trial is needed to strengthen our conclusions.
